KE

Kimball Electronics, Inc. (KE) - 10-K Summary

Business Context and Reporting Period

Company: Kimball Electronics, Inc. (trading symbol: KE)
Reporting Period: Fiscal year ended June 30, 2026
Business Overview: A global provider of electronics manufacturing services (EMS) and contract development and manufacturing organization (CDMO) solutions. The company serves automotive, medical, and industrial markets. In 2026, the company introduced the "Kimball Solutions" brand to reflect its expanded portfolio of non-electronic manufacturing solutions, including medical disposables and precision molded plastics. The company intends to change its name to Kimball Solutions, Inc., subject to shareholder approval.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 4% year-over-year, driven by a 7% decline in the automotive vertical (loss of a major program unrelated to Kimball) and a 5% decline in the industrial vertical. The medical vertical grew 4%.
• Profitability Expansion: Despite lower revenue, Net Income increased 65% and Operating Income increased 45%. This was driven by a 120 basis point improvement in gross margin (8.2% vs 7.0%) due to volume leverage in Europe, cost efficiencies from restructuring, and favorable foreign exchange rates.
• One-Time Gains: Operating income benefited significantly from a $14.7 million gain on the disposal of the Tampa facility (sold for $21.6 million) and a reduction in restructuring expenses ($5.0 million in 2026 vs $11.0 million in 2025).
• Tax Rate Increase: The effective tax rate rose to 47.5% in 2026 from 35.2% in 2025, primarily due to the recognition of dividend withholding taxes from foreign subsidiaries and GILTI income.
• Customer Concentration: Sales to the top three customers (Nexteer Automotive, Philips, and ZF) accounted for approximately 40% of net sales in 2026.

Guidance, Outlook, and Risks

• Strategic Acquisition: On July 1, 2026 (post-fiscal year end), the company acquired Helvoet Polymer Technologies B.V. for approximately $103 million. This expands capabilities in precision molded plastics and medical device components in India and the Netherlands.
• Future Trends (Fiscal 2027): Management expects results to be affected by Helvoet integration costs, start-up costs for a new Indianapolis medical CDMO facility, continued tariff uncertainty, and ongoing demand pressure in the automotive sector.
• Key Risks:
  • Customer Concentration: Loss of key customers or program cancellations could materially reduce revenue.
  • Supply Chain: Component shortages (particularly semiconductors) and geopolitical disruptions (Middle East, Russia-Ukraine) pose risks to operations and costs.
  • Trade Policy: Tariffs and trade restrictions could increase costs, though the company expects to recover a significant portion via contractual pass-throughs.
  • Acquisition Integration: Risks associated with integrating Helvoet's operations and realizing expected synergies.

Investor Verification Checklist

• Gain on Disposal: Verify the sustainability of operating income growth by excluding the $14.7 million one-time gain from the Tampa facility sale.
• Effective Tax Rate: Assess the impact of the 47.5% effective tax rate (driven by withholding taxes and GILTI) on future earnings projections.
• Automotive Exposure: Monitor the replacement of the lost major automotive program and the impact of cyclical demand in the automotive sector (46% of sales).
• Helvoet Integration: Track the integration progress and financial performance of the Helvoet acquisition in the first quarter of fiscal 2027.
• Working Capital: Review the increase in inventory ($19.9 million cash usage) and its impact on future cash conversion cycles.